National Institute of Allergy and Infectious Diseases, NIH: Volume 2: Impact on Global HealthNational Institute of Allergy and Infectious Diseases, NIH: Volume 2: Impact on Global Health covers the scientific aspects of the entire portfolio of NIAID, including microbiology and infectious disease, HIV/AIDS, and immunology and vaccines. All major diseases and the relevant immunology and vaccine development are described in detail. In addition, all major NIAID programs, initiatives, and clinical trials are discussed and illustrate the global involvement of NIAID in biomedical research and its impact on public health worldwide. By providing this information, the global scientific community will be able to access and benefit from these programs and initiatives. |
Contents
| 3 | |
| 19 | |
Fungal Diseases | 29 |
Virology | 41 |
Enteric Diseases | 49 |
Tuberculosis | 103 |
Viral Hepatitis | 125 |
The Typhus Group 193 | 192 |
Introduction | 337 |
Extramural Basic Research Programs | 359 |
Programs in HIVAIDS Therapeutics 375 | 374 |
Programs in HIV Vaccines | 381 |
HIVAIDS Epidemiology | 405 |
Antiretroviral Drugs and ImmuneBased Therapies | 415 |
Vaccine Development | 515 |
Opportunistic Infections | 531 |
Other editions - View all
National Institute of Allergy and Infectious Diseases, NIH: Volume 2: Impact ... Vassil St. Georgiev No preview available - 2009 |
Common terms and phrases
activity addition adults Africa agents AIDS animal antibodies antigen antiretroviral antiviral associated bacterial binding blood cause cells Centers changes clinical trials combination common compared complex containing currently daily disease dose drug effective efficacy emerging encephalitis et al evaluate expression factors fever function gene genetic genome Health hemorrhagic HIV infection host human human immunodeficiency identified immune immunodeficiency virus important increased infection influenza initial interactions International involved isolates known levels major malaria mechanism mutations natural NIAID observed occur organisms parasite pathogens patients Phase potential prevent production protease inhibitors protection protein recent receptor reduced regimens regions replication reported resistance response reverse risk safety sequence severe shown specific strains structure testing therapy tion transcriptase transmission treat treatment tuberculosis United vaccine viral virus viruses vitro weeks